miR-223 nanoparticle therapy for Alzheimer's neuroinflammation and ApoE control
MicroRNA lipid-nanoparticle based therapy targets neuroinflammation and ApoE dysregulation in Alzheimer’s disease
['FUNDING_R01'] · UNIVERSITY OF KENTUCKY · NIH-11241971
Trying a tiny RNA carried in lipid nanoparticles to reduce brain inflammation and correct ApoE-related problems in people living with Alzheimer's, with attention to effects that may differ in women.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF KENTUCKY (nih funded) |
| Locations | 1 site (LEXINGTON, UNITED STATES) |
| Trial ID | NIH-11241971 on ClinicalTrials.gov |
What this research studies
From a patient's perspective, researchers are packaging a naturally occurring microRNA called miR-223 into fat-like nanoparticles so it can reach immune cells in the brain and calm harmful inflammation. The team targets a pathway (CEBPβ → ApoE) that can become dysregulated with age, injury, or Alzheimer’s changes and appears to affect women more. So far the work has shown promising results in cells and mouse models while the team refines the nanoparticle delivery method. If those safety and effect signals continue, the approach could move toward testing in people.
Who could benefit from this research
Good fit: Ideal candidates for future trials would be older adults living with Alzheimer's disease or mild cognitive impairment, with particular attention to enrolling women due to observed sex differences.
Not a fit: People without Alzheimer's or whose symptoms are driven by unrelated conditions, and those with very advanced disease unlikely to respond to anti-inflammatory interventions, may not benefit.
Why it matters
Potential benefit: If successful, this approach could lower damaging brain inflammation and normalize ApoE activity, which might slow disease progression or reduce symptoms in Alzheimer's patients.
How similar studies have performed: Lipid-based delivery of RNA has worked for other therapies (for example mRNA vaccines and some RNA drugs), but using miR-223 to target CEBPβ/ApoE in Alzheimer's is a novel approach primarily tested so far in preclinical models.
Where this research is happening
LEXINGTON, UNITED STATES
- UNIVERSITY OF KENTUCKY — LEXINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WANG, WANG-XIA — UNIVERSITY OF KENTUCKY
- Study coordinator: WANG, WANG-XIA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired brain injury